



## Advances in Cancer Immunology

Guest Editor:

**Dr. Takumi Kumai**

Department Otolaryngol Head &  
Neck Surg, Asahikawa Med  
University, Midorigaoka East 2-1-  
1-1, Asahikawa 0788510, Japan

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editor

A tumor vaccine is an active method to specifically increase antitumor immune cells. In addition to CD8 T-cells, which play an essential role in tumor vaccination by directly killing tumor cells, innumerable reports have indicated that CD4 T-cells also have a direct cytotoxic activity against tumors. The main aim of this Special Issue is to gather the latest advances in the field of tumor immunology to optimize a tumor vaccine.

Potential topics for this Special Issue include, but are not limited to, the following:

- Immune adjuvants for a tumor vaccine;
- Immunological assessment of the tumor microenvironment;
- Combination of immunotherapy and chemoradiotherapy;
- Optimization of administration route and/or formula in a tumor vaccine;
- Immune cell polarization and immunotherapy;
- Impeding immune suppression in the tumor microenvironment;
- Re-education of immune cells in the tumor microenvironment;





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)